Investment Rating - The report indicates a positive outlook for the industry, particularly in sectors such as military, robotics, and new energy vehicles, driven by policy support and technological innovation [5][30]. Core Insights - The North Exchange A-shares saw a trading volume of 25.47 billion yuan on August 6, 2025, an increase of 5.49 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1459.51, up 1.58% [3][14]. - The report highlights that 198 out of 269 companies listed on the North Exchange experienced price increases, with notable gainers including Huami New Materials (30.0%) and Fuheng New Materials (16.0%) [25][28]. - The report emphasizes the ongoing structural opportunities in the market, supported by the release of policy dividends and the development of emerging technology industries [7]. Summary by Sections Market Review - On August 6, 2025, the North Exchange A-shares had a trading volume of 25.47 billion yuan, with the North Exchange 50 Index rising by 1.58% and the specialized index increasing by 2.15% [3][14]. - The report notes that the automotive, defense, construction materials, and basic chemicals sectors showed strong performance, with military and robotics themes gaining traction due to policy support and technological advancements [5][30]. Important News - The report mentions a government initiative aiming to complete the construction and renovation of 300,000 kilometers of rural roads by 2027, enhancing rural transportation infrastructure [30]. - It also highlights Shanghai's plan for the embodied intelligence industry, targeting a core industry scale of 50 billion yuan, focusing on technological innovation and market integration [32]. Key Company Announcements - Tonghui Electronics reported a half-year revenue of 100 million yuan, a year-on-year increase of 16.81%, with a net profit of 29 million yuan, up 55.4% [33]. - Other companies such as Chengdian Guangxin and Gebijia announced plans for share reductions by major shareholders [35][36].

Investment Rating - The report indicates a positive outlook for the industry, particularly in sectors such as defense, robotics, and automotive, driven by policy support and technological innovation [3][6][18]. Core Insights - The North Exchange A-share trading volume reached 25.47 billion yuan on August 6, 2025, an increase of 5.49 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1459.51, up 1.58% [6][15]. - The report highlights that 198 out of 269 companies listed on the North Exchange saw their stock prices rise, with significant gains in companies like Huami New Materials (30.0%) and Fuheng New Materials (16.0%) [15][17]. - The report emphasizes the ongoing support from the central bank and other departments for new industrialization policies, which bolster market confidence in the growth potential of North Exchange companies [3][18]. Summary by Sections Market Review - On August 6, 2025, the North Exchange A-share trading volume was 25.47 billion yuan, with the North Exchange 50 Index increasing by 1.58% and the PE_TTM at 68.36 times [6][13]. - The North Exchange specialized index closed at 2516.96, reflecting a 2.15% increase [6][13]. Stock Performance - Among the 269 companies, 198 experienced price increases, while 68 saw declines. The top five gainers included Huami New Materials (30.0%), Fuheng New Materials (16.0%), and Mingyang Technology (15.7%) [15][17]. - The top five decliners were Sanyuan Gene (-6.1%), Hengli Drill Tools (-5.6%), and Beiyikang (-3.7%) [15][17]. Important News - The Ministry of Transport, Ministry of Finance, and Ministry of Natural Resources aim to complete the renovation of 300,000 kilometers of rural roads by 2027, enhancing safety and service capabilities [18]. - Shanghai's embodied intelligence industry plan targets a core industry scale of 50 billion yuan, focusing on technological innovation and support for applications [19]. Company Announcements - Tonghui Electronics reported a 16.81% year-on-year increase in revenue to 100 million yuan, with a net profit growth of 55.4% [20]. - Shareholder announcements included planned reductions in holdings by major stakeholders in Chengdian Guangxin and Gebijia [22][23].

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.14% on August 1, with Sanyuan Gene leading the drop [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wanzhe Co., Ltd. (000534) with a closing price of 15.74, up 9.99% and a trading volume of 289,100 shares [1] - Rili Pharmaceutical (603087) closed at 60.99, up 5.34% with a trading volume of 288,400 shares [1] - Wuxi Jinghai (836547) closed at 27.78, up 4.83% with a trading volume of 47,200 shares [1] - Conversely, significant decliners included: - Sanyuan Gene (837344) with a closing price of 31.22, down 9.51% and a trading volume of 84,300 shares [2] - Shenzhou Cell (688520) closed at 69.52, down 7.06% with a trading volume of 103,100 shares [2] - Norsland (430047) closed at 23.73, down 5.04% with a trading volume of 107,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 278 million yuan from institutional investors, while retail investors contributed a net inflow of 172 million yuan [2] - The capital flow for specific stocks indicated: - Wanzhe Co., Ltd. had a net inflow of 116 million yuan from institutional investors, but a net outflow from retail investors [3] - Kexing Pharmaceutical (688136) experienced a net inflow of 69.89 million yuan from institutional investors [3] - Kanghua Biological (300841) had a net inflow of 52.58 million yuan from institutional investors [3]

Summary of Key Points Core Viewpoint - As of July 31, the total margin financing and securities lending balance on the Beijing Stock Exchange (BSE) was 6.33 billion yuan, showing a decrease of 11.37 million yuan from the previous trading day, indicating a slight contraction in market activity [1]. Financing and Margin Data - The financing balance was 6.33 billion yuan, down by 11.32 million yuan, while the securities lending balance was 71.83 thousand yuan, down by 5.50 thousand yuan [1]. - The stocks with the highest financing balances included Jinbo Biological (360 million yuan), Airon Software (166 million yuan), and Better Ray (166 million yuan), with an average financing balance to market capitalization ratio of 1.19% [1]. - The stocks with the highest ratios of financing balance to market capitalization were Shengye Electric (5.25%), Wanyuantong (4.01%), and Litong Technology (3.54%) [1]. Sector Performance - In terms of industry statistics, the sectors with the most stocks receiving net financing above 1 million yuan were machinery equipment (11 stocks), pharmaceutical biology (4 stocks), and automotive (3 stocks) [2]. - On July 31, stocks with net financing above 1 million yuan had an average increase of 11.91%, with notable gainers including Dingjia Precision (up 479.12%), Hujiang Materials (up 4.16%), and Xinjiang (up 3.46%) [2]. - Conversely, 27 stocks experienced declines, with the largest drops seen in Wuxin Tunnel Equipment, Guangzi International, and Zizhong Palace [2]. Trading Activity - The weighted average turnover rate for stocks with net financing above 1 million yuan was 6.32%, with the highest turnover rates recorded for Dingjia Precision (89.34%), Xinjiang (19.36%), and Wanyuantong (18.18%) [2]. - The average daily turnover rate for BSE stocks on that day was 4.52% [2]. Notable Stocks - The stocks with the largest increases in financing balance included Wuxin Tunnel Equipment (increase of 12.68 million yuan), Sanyuan Gene (increase of 9.71 million yuan), and Deyuan Pharmaceutical (increase of 8.65 million yuan) [2][3]. - Other notable stocks with significant financing balance increases were Wanyuantong, Huifeng Diamond, and Dingjia Precision, with respective increases of 7.33 million yuan, 4.78 million yuan, and 4.25 million yuan [2][3].

Investment Rating - The report suggests a focus on sectors such as innovative pharmaceuticals, AI hardware, and childcare subsidies, indicating a positive outlook for these areas [4][18]. Core Insights - The market is experiencing a rebound, with the North Exchange A-share trading volume reaching 26.42 billion yuan, an increase of 2.19 billion yuan from the previous trading day. The North Exchange 50 Index closed at 1465.32, up 0.68%, with a PE_TTM of 68.41 times [2][8]. - The report highlights strong performance in the innovative pharmaceutical sector, driven by national childcare subsidy policies and industry R&D advancements, with companies like Sanmian Gene seeing a rise of over 20% [4][15]. - The report anticipates a mixed market in the short term but expects resilience in the medium to long term due to policy dividends and industrial upgrades [4]. Summary by Sections Market Review - On July 29, the North Exchange A-share trading volume was 26.42 billion yuan, with 268 companies listed. Among these, 98 companies rose, 8 remained flat, and 162 fell [2][15]. - The top five gainers included Sanmian Gene (20.80%), Jikang Instrument (20.40%), and Huaitong New Materials (14.20%) [15][17]. Important News - The establishment of the third state-owned automobile enterprise, China Chang'an Automobile Group, aims to enhance the development of intelligent connected new energy vehicles [18]. - The report also mentions the establishment of a new semiconductor photomask company in Anhui, which will focus on producing photomasks for 28nm and above process nodes [19]. Key Company Announcements - Yintu Network received 10 software copyright registration certificates from the National Copyright Administration [3][24]. - Zhongcheng Technology signed a cooperation agreement with China Mobile for a big data cloud platform service project worth 50.52 million yuan [3][20]. - Sanmian Gene announced the approval of a new drug, recombinant human interferon α1b spray, by the National Medical Products Administration [3][22].

每经讯，2025年7月29日，北交所上市公司三元基因（837344，收盘价：34.84元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日收盘价涨幅达到20.76%，成交数量1438.74万股，成交金额4.83亿元。买一席位为国金证券股份有限公司深圳分公司，买 入1112.04万元；卖一席位为国泰海通证券股份有限公司深圳海岸城海德三道营业部，卖出1367.66万元。 | | 2025-07-29三元基因(837344) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | ポリ | 国金证券股份有限公司深圳分公司 | 11120395.2 | 5765598.34 | | 买2 | 机构专用 | 9274827.26 | 4197721.83 | | 考3 | 国联民生证券股份有限公司国联民生证券北京分公司 | 8837973.24 | 0 | | 买4 | 国信证券股份有限公司深圳红岭中路证券营业部 | 8127951.58 | 6179868.15 | | ન્નેર | 东方财富证券股份有限公司拉萨团结路第二 ...

证券日报网讯7月29日晚间，三元基因发布公告称，近日，公司收到国家药品监督管理局核准签发的重 组人干扰素α1b喷雾剂(25万IU(25μg)：5ml/支)《药品补充申请批准通知书》。 ...

Group 1 - The pharmaceutical sector showed strong performance on July 29, with several stocks experiencing significant gains [2] - Sanmgen (837344.BJ) led the market with a 20.76% increase, followed by Ruizhi Pharmaceutical (300149.SZ) and Yaoshi Technology (300725.SZ), which rose by 20.02% and 18.77% respectively [2] - Other companies such as Aoxiang Pharmaceutical, Asia-Pacific Pharmaceutical, Chenxin Pharmaceutical, Renmin Tongtai, and Jiuzhou Pharmaceutical also reached their daily limit up [2] Group 2 - Market analysis suggests that the strong performance of the pharmaceutical sector may be attributed to favorable policies and an increase in industry prosperity [2]

证券代码：837344 证券简称：三元基因 公告编号：2025-052 剂型：喷雾剂 注册分类：治疗用生物制品 规格：25 万 IU（25μg）：5ml/支 北京三元基因药业股份有限公司关于 重组人干扰素 α1b 喷雾剂 获得《药品补充申请批准通知书》的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 近日，北京三元基因药业股份有限公司（以下简称"公司"）收到 国家药品监督管理局核准签发的重组人干扰素 α1b 喷雾剂（25 万 IU （25μg）：5ml/支）《药品补充申请批准通知书》，现将有关情况公告如 下： 一、《药品补充申请批准通知书》主要内容 药品名称：重组人干扰素 α1b 喷雾剂 商品名称：运德素 公司重组人干扰素 α1b 喷雾剂获得《药品补充申请批准通知书》， 将能够进一步增加医生与患者的用药选择，更好地满足临床治疗需求， 巩固并提升公司产品的品牌效应和市场竞争力。 四、风险提示 该药品未来的生产和销售情况受到市场环境和国家政策等因素 的影响，存在不确定性，敬请广大投资者谨慎决策，注意防 ...